QOL Medical, LLC
6
0
0
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
50.0%
3 terminated/withdrawn out of 6 trials
50.0%
-36.5% vs industry average
33%
2 trials in Phase 3/4
67%
2 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure
Role: collaborator
7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels
Role: lead
Effects of Sacrosidase and Placebo in Subjects With Fructan Intolerance
Role: lead
Adult Pilot Study for Reference Ranges and Optimal Cut-offs for the Sucrose Challenge Test and Sucrose Breath Test
Role: lead
Congenital Sucrase-Isomaltase Deficiency (CSID) Genetic Prevalence Study (GPS)
Role: lead
A Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency
Role: lead
All 6 trials loaded